



Correction to: Benefit:Risk Profile of Budesonide in Obstructive Airways Disease

Donald P. Tashkin¹ · Brian Lipworth² · Ralph Brattsand³

Published online: 5 November 2019
© Springer Nature Switzerland AG 2019

Correction to: *Drugs* (2019) 79:1757–1775
<https://doi.org/10.1007/s40265-019-01198-7>

Page 5, Fig. 2 Key milestones in the development of budesonide.

Box that currently reads ‘First approval of budesonide nebuliser solution for use in asthma 1992’

Should read:

‘First approval of budesonide nebuliser suspension for use in asthma 1992’

The original article can be found online at <https://doi.org/10.1007/s40265-019-01198-7>.

✉ Donald P. Tashkin
dtashkin@mednet.ucla.edu

¹ Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1690, USA

² Scottish Centre for Respiratory Research, Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, UK

³ Experimental Pharmacology, Budera Company, Kristinehamn, Sweden